Jean-Jacques Garaud, MD Global Head Pharma ... - Roche
Jean-Jacques Garaud, MD Global Head Pharma ... - Roche
Jean-Jacques Garaud, MD Global Head Pharma ... - Roche
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Exciting mid- and early-stage opportunities in oncology<br />
IGF1-R Inhibitor – Impressive early results<br />
Potential broad use in cancer therapy<br />
3rd generation anti-CD20<br />
Potential for improvement over MabThera<br />
Increased direct cell death<br />
Increased ADCC<br />
Lower CDC<br />
Restaging Week 6<br />
Unique Features: Selective to IGF pathway<br />
which is a key factor in tumor growth<br />
Drivers of Value: IGF pathway linked to many<br />
tumor types<br />
Phase I in NHL<br />
Unique Features: fully humanized MAb<br />
recognizing type II CD 20 epitope<br />
Drivers of Value: superior to rituximab in vitro<br />
and in pre-clinical models<br />
Phase II ongoing<br />
Phase I data at ASH<br />
ADCC= (antibody dependent cell-mediated cytotoxicity); CDC= (complement dependent cytotoxicity)<br />
20
Change language